Novo also offers the 1.5 mg starter dose for its oral semaglutide drug for type 2 diabetes, sold as Rybelsus
The STEP (Semaglutide Treatment Effect in People with obesity) trial program showed average weight reductions of approximately 15% of initial body weight over 68 weeks in individuals without diabetes, with somewhat lower reductions (about 9-10%) in those with type 2 diabetes
Patient Assessment Regular follow-ups help monitor progress, weight loss, and any side effects
Eur J Biochem 267:49044911 Krahenbuhl S, Krahenbuhl-Glauser S, Stucki J, Gehr P, Reichen J (1992) Stereological and functional analysis of liver mitochondria from rats with secondary biliary cirrhosis: impaired mitochondrial metabolism and increased mitochondrial content per hepatocyte
Product packaging may differ from images or descriptions
These side effects are most frequent during the initial weeks and when increasing the dose but tend to improve over time